GPC3 and neoplasm: Recent advances in immunotherapy have brought Glypican-3 (GPC3) into focus as a prime therapeutic target - this heparan sulfate proteoglycan demonstrates tumor-specific overexpression in 70% of HCC cases while maintaining near absence in normal liver tissue (6, 7).